DHEA (dehydroepiandrosterone) is a hormone precursor produced mainly by the adrenal glands, and it serves as the raw material your body uses to make estrogen and testosterone inside individual tissues. For women, the practical interest in DHEA centers on a handful of areas where supplementation has real evidence behind it: relieving vaginal dryness after menopause, supporting bone density, and restoring well-being in women with adrenal insufficiency. Beyond those, the picture gets murkier, with studies on sexual desire, mood, fertility, and metabolic health pulling in different directions.
Why DHEA Matters More as You Age
DHEA and its sulfate form (DHEA-S) are the most abundant steroid hormones circulating in the human body. Their levels peak in the mid-twenties and then drop steadily, falling to roughly 10 to 20 percent of youthful levels by the time a woman reaches her seventies or eighties.1PubMed Central. A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? This decline has been called “adrenopause,” and it occurs in both sexes, though it carries particular consequences for women because DHEA is the dominant source of androgens in the female body after menopause.
Unlike testosterone in men, which comes mainly from the testes, androgens in women are largely manufactured inside individual cells from DHEA supplied by the adrenal glands. Specialized enzymes in bone, brain, fat, skin, and vaginal tissue convert DHEA into small, locally active amounts of testosterone and estrogen right where those hormones are needed.2PubMed. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology When the supply of DHEA dwindles with age, each of those tissues loses some of its ability to produce the sex hormones it depends on.3PubMed. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology This is the basic rationale for DHEA supplementation: replenish the precursor and let each tissue decide what to do with it.
Vaginal Health After Menopause
The strongest clinical evidence for DHEA in women involves intravaginal use for vulvovaginal atrophy, the thinning and drying of vaginal tissue that affects a large proportion of postmenopausal women and frequently causes pain during sex. An FDA-approved intravaginal insert containing DHEA (sold as Intrarosa / prasterone) works by delivering the hormone directly to vaginal cells, which convert it locally into the estrogen and androgen they need to maintain healthy tissue.
In clinical trials, daily intravaginal DHEA at a 0.50% concentration for 12 weeks produced significant improvements over placebo across every standard measure of vaginal health: the proportion of superficial cells lining the vagina increased, vaginal pH dropped, pain during sex decreased, and vaginal dryness improved. At gynecological examination, vaginal secretions, tissue integrity, surface thickness, and color all improved by roughly 86 to 121 percent beyond the placebo effect.4PubMed. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause Earlier dose-finding work showed that benefits appeared within two weeks, and 0.25%, 0.50%, and 1.0% doses all produced comparable improvements.5PubMed. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy
Because intravaginal DHEA is converted inside the tissue itself and does not meaningfully raise blood levels of estrogen, it is considered a local treatment rather than systemic hormone therapy. This matters for women who want to avoid or cannot use systemic estrogen, including some breast cancer survivors, though anyone in that situation should discuss it with their oncologist before starting.
Sexual Desire and Arousal
Whether oral DHEA supplements improve sexual function in otherwise healthy women is far less clear than the vaginal-health story. The research here is a patchwork of small studies with conflicting results.
One trial that specifically enrolled women diagnosed with low sexual desire found that DHEA at 100 mg per day for six weeks significantly improved sexual arousal compared to placebo, an effect that appeared to be driven by DHEA’s conversion to testosterone. The researchers noted that this benefit showed up only in women, not in men enrolled in the same study.6PubMed. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences However, a separate randomized trial of 50 mg per day in postmenopausal women with low libido found no meaningful difference between DHEA and placebo on sexual events, satisfaction, or menopausal symptoms.7PubMed. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido
A systematic review of randomized controlled trials concluded that the evidence for DHEA improving libido or well-being in healthy women is limited by small sample sizes and short treatment durations, with inconsistent results overall.8PubMed. DHEA therapy for women: effect on sexual function and wellbeing The dose seems to matter; the positive arousal trial used 100 mg per day, while the negative one used 50 mg. But whether doubling the dose would consistently work is something larger studies haven’t confirmed. If you are considering DHEA specifically for sexual desire, the honest answer is that it might help some women, but the evidence is too uneven to call it reliable.
Fertility and IVF
DHEA has attracted interest as a pre-treatment for women with diminished ovarian reserve who are undergoing IVF. The idea is that androgens derived from DHEA promote the growth of small developing follicles in the ovary, potentially improving the pool of eggs available for retrieval.
A meta-analysis pooling several studies found that DHEA use was associated with roughly 80 percent higher odds of pregnancy and a significant reduction in miscarriage rates among women with diminished ovarian reserve.9PubMed Central. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis A narrative review supported this direction, suggesting DHEA may reduce chromosomal abnormalities in embryos and gradually improve ovarian reserve markers over time.10PubMed Central. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)
But an earlier meta-analysis that looked at about 200 total IVF cycles reached a much more cautious conclusion: it found no significant difference in clinical pregnancy rates or miscarriage rates, and the DHEA group actually had fewer oocytes retrieved.11PubMed Central. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis This disagreement between meta-analyses reflects the overall state of the evidence: the studies vary widely in design, dosing, and how long women took DHEA before their IVF cycle. Many fertility clinics do recommend DHEA supplementation (usually 75 mg per day for at least six to eight weeks before egg retrieval), but it remains off-label and far from proven.
Bone Density
DHEA appears to have a modest but real effect on bone density in women, concentrated mainly at the lumbar spine. A 12-month randomized trial in older adults found that DHEA supplementation increased lumbar spine bone mineral density by about 2.2 percent in women compared to placebo, though no significant changes were seen at the hip in women specifically.12The Journal of Clinical Endocrinology & Metabolism. Effects of Dehydroepiandrosterone Replacement Therapy on Bone Mineral Density in Older Adults: A Randomized, Controlled Trial Another trial (the DAWN trial) found a similar result: DHEA had a positive effect on lumbar spine density in women but not men, and it increased testosterone, estradiol, and IGF-1 levels in women but not men.13PubMed Central. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults the DAWN trial
A Mendelian randomization study using genetic data took this further by suggesting that the relationship between DHEA-S levels and lumbar spine bone density is causal, not just correlational. The analysis found that genetically higher DHEA-S levels were linked to meaningfully higher spine density and lower risk of forearm fractures in women.14The Journal of Clinical Endocrinology & Metabolism. Endogenous DHEAS Is Causally Linked With Lumbar Spine Bone Mineral Density and Forearm Fractures in Women These effects seem to be driven by DHEA’s conversion to estrogen and testosterone within bone cells. The gains are modest compared to prescription osteoporosis drugs, but for a woman looking at supplementation for multiple reasons, bone density is a legitimate secondary benefit.
Adrenal Insufficiency
Women with adrenal insufficiency (such as Addison’s disease) represent the clearest medical case for DHEA supplementation. Because their adrenal glands cannot produce DHEA at all, they have near-zero levels and lose essentially all adrenal androgen activity. Standard hormone replacement for these patients covers cortisol and sometimes aldosterone but traditionally ignores DHEA.
A landmark trial published in the New England Journal of Medicine found that four months of DHEA replacement in women with adrenal insufficiency restored androgen levels to the normal range, significantly improved overall well-being, and reduced scores for depression and anxiety. It also significantly increased the frequency of sexual thoughts, sexual interest, and satisfaction with both mental and physical aspects of sexuality.15PubMed. Dehydroepiandrosterone replacement in women with adrenal insufficiency Another trial in women with Addison’s disease confirmed that 50 mg daily restored DHEA-S and androgen levels to the normal range, though it also noted common androgenic side effects like acne and increased sweating.16PubMed. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison’s disease
A longer-term randomized trial over 12 months found that DHEA reversed ongoing bone loss at the femoral neck and improved lean body mass in patients with primary adrenal insufficiency. The benefits for psychological well-being were more mixed at the longer timepoint, with only one quality-of-life subscale reaching significance, and no clear benefit for fatigue, cognition, or sexual function over a full year.17The Journal of Clinical Endocrinology & Metabolism. Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial This suggests that the initial mood and sexuality boost seen in shorter trials may partly fade with time, though the metabolic and bone benefits persist.
Body Composition and Insulin Sensitivity
One well-known trial published in JAMA gave 50 mg of DHEA daily or placebo to older women and men for six months and found that DHEA produced significant decreases in both visceral (deep belly) fat and subcutaneous fat. The insulin response during a glucose tolerance test dropped substantially in the DHEA group while blood sugar stayed the same, meaning insulin sensitivity improved.18PubMed. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial This result generated excitement about DHEA as a metabolic agent, but it has not been consistently replicated. A later trial in older women with frailty characteristics found that despite changes in hormone levels, DHEA did not significantly alter lipid profiles, body fat, fasting glucose, or blood pressure.19PubMed Central. Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics The metabolic picture remains inconclusive, and DHEA should not be relied on as a weight-loss or diabetes-prevention strategy.
Mood and Depression
DHEA’s role in mood is one of the more intriguing areas, though the evidence splits depending on who is being treated and what kind of mood problem they have. A small trial in patients with midlife dysthymia (a chronic, low-grade depression) found a strong effect: 60 percent of patients responded to DHEA after six weeks, compared with 20 percent on placebo. Symptoms that improved most included low energy, lack of motivation, emotional numbness, and anhedonia.20PubMed. Dehydroepiandrosterone treatment of midlife dysthymia
For perimenopausal women without a diagnosed mood disorder, though, DHEA supplementation has not delivered. A three-month trial in perimenopausal women given 50 mg daily found no improvements over placebo in mood, dysphoria, cognition, memory, or overall well-being, despite the expected changes in hormone levels.21The Journal of Clinical Endocrinology & Metabolism. The Effect of Deydroepiandrosterone Supplementation to Symptomatic Perimenopausal Women on Serum Endocrine Profiles, Lipid Parameters, and Health-Related Quality of Life A similar pattern shows up for cognition: one small study in older women with mild cognitive impairment found that DHEA improved cognitive scores over six months while the control group declined,22PubMed. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment but a separate study in healthy elderly people found no meaningful cognitive or well-being effects from a two-week course of DHEA replacement.23The Journal of Clinical Endocrinology & Metabolism. Effects of a Two-Week Physiological Dehydroepiandrosterone Substitution on Cognitive Performance and Well-Being in Healthy Elderly Women and Men
The pattern across mood and cognitive studies is consistent: DHEA seems to help people who are clearly deficient or clinically impaired, and it does little for those who are basically well. If you are dealing with a diagnosed mood disorder, DHEA is worth discussing with a doctor, but taking it as a general wellness supplement for mood is not well supported.
Lupus
Systemic lupus erythematosus (SLE), which disproportionately affects women, is another condition where DHEA has been tested. Women with lupus tend to have low DHEA levels, and there has been interest in whether supplementation could reduce disease flares and allow patients to lower their corticosteroid doses. A large double-blind trial found that among women with active lupus, 51 percent of those receiving 200 mg of DHEA daily were classified as treatment responders, compared with 29 percent on placebo.24PubMed. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial A review of the literature concluded that DHEA could improve quality-of-life measures and reduce steroid requirements in some patients with mild to moderate lupus, though its effect on underlying disease activity remains controversial.25PubMed Central. Dehydroepiandrosterone in systemic lupus erythematosus DHEA was actually granted FDA orphan drug status for lupus at one point, though it never became a standard-of-care treatment.
Side Effects and Androgenic Risks
Because DHEA is converted into androgens, the most common side effects in women are predictably androgenic: acne, oily skin, and increased facial or body hair growth. A randomized trial in postmenopausal women noted that while overall adverse events were similar between DHEA and placebo groups, more women on DHEA experienced acne and extra hair growth specifically.26The Journal of Sexual Medicine. A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido These effects are dose-dependent and generally reversible once DHEA is stopped.27PubMed. DHEA: why, when, and how much–DHEA replacement in adrenal insufficiency At higher doses (200 mg per day), some women in adrenal insufficiency trials achieved supraphysiological androgen levels and experienced more pronounced side effects.
A more serious concern is the potential relationship between DHEA and breast cancer. Because DHEA can be converted into estrogen, there is biological plausibility for it promoting estrogen-sensitive tumors. Epidemiological studies have reported a positive correlation between higher circulating DHEA levels and breast cancer risk in postmenopausal women, with the association being stronger for hormone-receptor-positive tumors.28PubMed. Functions of dehydroepiandrosterone in relation to breast cancer An earlier review similarly noted that prolonged DHEA intake might stimulate late promotion of breast cancer in postmenopausal women, with pre-existing abdominal obesity potentially increasing the risk.29PubMed. Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk No randomized trial has been designed or powered to test this risk directly, so it remains theoretical but biologically grounded. Women with a personal or strong family history of breast cancer should be cautious.
The Supplement Quality Problem
In the United States, DHEA is sold as a dietary supplement rather than a prescription drug. This means the products on store shelves have not been evaluated by the FDA for safety or efficacy, and manufacturers are not required to follow the same manufacturing standards as pharmaceutical companies.30JAMA. Quality Control of Dehydroepiandrosterone Dietary Supplement Products Quality-control testing of DHEA supplements has historically found that the actual hormone content can vary substantially from what the label claims. Some products contain considerably less DHEA than stated, others more. If you are taking DHEA, especially at a specific dose based on clinical trial evidence, this variability matters. Choosing brands that have been independently tested by a third-party lab (look for USP, NSF, or ConsumerLab seals) reduces but does not eliminate this risk.
The regulatory landscape differs outside the U.S. In many European and Asian countries, DHEA is classified as a prescription medication rather than a supplement, which subjects it to pharmaceutical manufacturing and dosing standards. The FDA-approved intravaginal formulation (prasterone) does go through standard drug regulation and is consistent from batch to batch, which is one reason clinicians tend to be more comfortable recommending it for vaginal atrophy than recommending over-the-counter oral DHEA for other purposes.
Who Should and Should Not Consider DHEA
The women most likely to benefit from DHEA fall into a few distinct groups. Women with diagnosed adrenal insufficiency have the strongest case, since they are genuinely deficient and supplementation restores something they are missing. Postmenopausal women with vaginal dryness or pain during sex have robust trial data supporting intravaginal DHEA specifically. Women with diminished ovarian reserve who are pursuing IVF may benefit, though the evidence is still debated and their fertility specialist should guide the decision.
For healthy women who feel tired, have a low mood, or want to slow aging, the evidence for oral DHEA supplements is not compelling. Most well-designed trials in healthy women have found that DHEA changes hormone levels on blood tests without translating into noticeable improvements in well-being, energy, or sexual function. The hormone-level change is real; the clinical benefit is not consistently there.
Women who should avoid DHEA or use it only under medical supervision include those with hormone-receptor-positive breast cancer or a strong family history of it, women with polycystic ovary syndrome (who already tend to have elevated androgens), and anyone taking hormone therapy, since DHEA will add to the total hormone load. Liver conditions warrant caution too, since oral DHEA passes through the liver. If you do take it, starting at the lowest dose that has been studied (25 to 50 mg per day for oral, 6.5 mg for the vaginal insert) and monitoring both symptoms and blood levels with your doctor is the sensible approach.